Today: 21 May 2026
Shell stock rises as buyback keeps ticking — what to watch before earnings
14 January 2026
1 min read

Shell stock rises as buyback keeps ticking — what to watch before earnings

New York, Jan 14, 2026, 03:14 EST — Market closed

Shell’s U.S.-listed shares closed Tuesday 2.1% higher at $73.18, buoyed by stronger energy sector momentum following a fourth consecutive rise in crude prices.

The shift is significant as traders weigh a complicated blend: geopolitical tensions affecting oil, new Q4 earnings reports from Big Oil, and a continuous stream of share buybacks propping up the sector.

Shell disclosed it repurchased 1,677,480 shares for cancellation on Jan. 13, split between its London and Amsterdam listings. This move is part of a buyback programme the company unveiled in late October.

Oil dipped slightly early Wednesday, with Brent slipping about 0.6% in Asia following Venezuela’s restart of exports and data showing a hefty rise in U.S. crude inventories. “Unless we see further escalation and chances of actual disruption in oil flows, the market could consolidate at these levels,” said Suvro Sarkar, energy analyst at DBS Bank. Reuters

BP in Europe reported $4 billion to $5 billion in fourth-quarter impairments, mostly hitting its energy transition units, and also signaled weakness in oil trading.

Shell says its buyback is planned to last roughly three months and, depending on market conditions, aims to wrap up before the company releases fourth-quarter results.

Shell shares climbed 2.27% in London on Tuesday, ending the day at 27.22 pounds. The rise outpaced a stagnant FTSE 100 and tracked gains across the oil and gas sector.

The floor beneath the group isn’t fixed. Should Venezuelan barrels continue to pour in, and U.S. inventory reports show supply easing, crude might drop sharply—and energy stocks could tumble just as fast.

Shell’s next major event is the release of its fourth-quarter results and interim dividend, scheduled for Feb. 5 at 0700 GMT. Oil market fluctuations leading up to that date will probably influence investor sentiment ahead of the announcement.

Stock Market Today

  • Thales (ENXTPA:HO) Shares Decline but DCF Model Indicates Undervaluation
    May 21, 2026, 1:56 AM EDT. Shares of Thales (ENXTPA:HO) have fallen 12.8% over the past month and are down 9.7% year on year, despite strong long-term returns of 79.2% and 203.0% over three and five years respectively. Recent sector-specific developments in aerospace and defense, alongside broader market sentiment, contribute to price volatility. A discounted cash flow (DCF) analysis estimates Thales's intrinsic value at around €306.76 per share, suggesting the current price of €229.50 trades at a 25.2% discount and that the stock is undervalued. The P/E ratio remains a key metric but further valuation aspects need evaluation, as Thales scores 4 out of 6 on Simply Wall St's valuation checks. Investors should consider these factors when assessing the stock's potential.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP
Previous Story

BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP

Australia stock market today: ASX 200 ends at two-month high as oil and copper lift miners, banks slide
Next Story

Australia stock market today: ASX 200 ends at two-month high as oil and copper lift miners, banks slide

Go toTop